A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13

A Phase 3, Randomized, Blinded, Active-controlled Study to Evaluate the Immunogenicity and Safety of Walvax's 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13-TT) as Compared to Pfizer's 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Co-administered With EPI Vaccines at 2, 4, and 12-15 Months of Age, to Healthy Infants in Indonesia

Hypothesis of non-inferiority test for seropositive rate and GMC in each serotype

Study Overview

• Status: Enrolling by invitation
• Conditions: Pneumococcal Disease, Invasive
• Intervention / Treatment: Biological: Walvax PCV13-TT; Biological: Pfizer PCV13

Detailed Description

H0: the immune responses elicited by PCV13-TT are inferior to those elicited by PCV13

HA: the immune responses elicited by PCV13-TT are non-inferior to those elicited by PCV13.

Non-inferiority of the immune responses elicited by PCV13-TT will be declared if both of the following criteria are met: (1) the lower limit of the 2-sided 95% CI of the difference (PCV13-TT-PCV13) in proportions of responders who achieving the threshold of 0.35 µg/ml is >-10%; and (2) the lower limit of the 2-sided 95% CI of the GMC ratio (PCV13-TT/PCV13) is >0.5. Thus, the familywise type I error will not be inflated.

• Study Type: Interventional
• Enrollment (Estimated): 600
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Lei Shi; Phone Number: +8619912789963; Email: lei.shi@walvax.com

Study Locations

• Indonesia
  • Bali
    • Denpasar, Bali, Indonesia, 80114
      • RSUP Prof. Dr. I.G.N.G Ngoerah
  • Jakarta
    • Jakarta Pusat, Jakarta, Indonesia, 10430
      • Ilmu Kesehatan anak FKUI RSCM

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Infants must meet ALL the following inclusion criteria for enrollment in the study, at the time of the screening:

  1. Healthy infants based on medical history and clinical assessment.
  2. Age of 6-8 weeks at enrolment. Infants will be eligible since the day they reach 6 weeks of age and until 8 weeks of age included.
  3. Body weight at enrollment ≥3.5 kg.
  4. Infant's parent(s) or legal guardian(s) must be able and willing to provide voluntary written/thumb-printed informed consent for the infant to participate in the study.
  5. Infant's parent(s) or legal guardian(s) must be able to comprehend and comply with study requirements and procedures and must be willing and able to return or make themselves available for all scheduled follow-up visits.
  6. Infant's parents must have a readily identifiable place of residence in the study area, be available for the duration of trial participation, and have means of telephone contact.

Exclusion Criteria:

• The following criteria should be checked at the time of study entry. If ANY exclusion criterion applies, the subject must not be included in the study:

  1. Use of any investigational medicinal product prior to randomization or planned use of such a product during the period of study participation.
  2. History of S. pneumoniae infection as confirmed by medical enquiry or as confirmed by laboratory testing if available.
  3. Participant has fever (axillary temperature ≥ 37.5℃) within 24 hours prior to the 1st dose of vaccination; (If the subject does not meet the criteria, the visit may be rescheduled when the criteria are met.)
  4. The infant who are children in care, preterm and low-birth-weight(Preterm infants have a gestational age below 37 weeks at birth and low-birth-weight infants have a birth weight below 2.5 kg).
  5. History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the 2 study vaccines. This includes all components of the EPI vaccines.
  6. History of anaphylactic shock.
  7. Any abnormal vital sign.
  8. Any moderate or severe acute illness.
  9. History of administration of a non-study vaccine within 30 days prior to administration of study vaccine, other than EPI vaccinations (Note: EPI vaccines other than that stipulated in the study must be given at least 14 days prior to the investigational vaccine.)
  10. Individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids (if systemic corticosteroids are administered for 14 days at a dose of 20 mg/day of prednisone or equivalent), e.g., for cancer or an autoimmune disease, or planned receipt throughout the study. Inhaled/nebulized, intra-articular, epidural, or topical (skin or eyes) corticosteroids within indicated dosage are permitted.
  11. Administration of immunoglobulins and/or any blood products or anticipation of such administration during the study period.
  12. History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding (e.g., thalassemia, coagulation factor deficiencies, severe anemia at birth).
  13. History of suspected primary immunodeficiency.
  14. History of meningitis, seizures or any neurological disorder.
  15. A family history of congenital or hereditary immunodeficiency.
  16. The infant is a direct descendant (child or grandchild) of any person employed by the Sponsor, the CRO, the investigator, study site personnel.
  17. Any medical or social condition that in the opinion of the investigator may compromise the well-being of the study participant, interfere with the study objectives, pose a risk to the study participant, or prevent the study participant from completing the study follow-up.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Walvax PCV13-TT; Primary Vaccination: A total of approximately 300 infants 6-8 weeks of age will be enrolled and assigned randomly to receive at 2, 4, and 12-15 months of age 1 dose of PCV13-TT. Standard EPI vaccines will be administered concomitantly. Booster Vaccination: At 12-15 months of age (8 to 11 months after the 2nd dose of the primary series), infants will receive a booster dose of PCV13-TT.	Biological: Walvax PCV13-TT; PCV13-TT is supplied as 0.5 mL prefill syringe (PFS), with 0.5 mL suspension for intramuscular injection. After shaking, the vaccine is a homogenous, white suspension. Each dose (0.5 mL) of PCV13-TT contains pneumococcal polysaccharide serotypes 1, 3 4, 5, 6A 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F which are conjugated to TT carrier protein individually. The vaccine is formulated in phosphate-buffered saline containing 4.25 mg/dose sodium chloride (NaCl), 44.35 μg/dose sodium dihydrogen phosphate (NaH2PO4), 19.0 μg/dose disodium hydrogen phosphate (Na2HPO4), and contains 0.5 mg/dose of aluminum phosphate as an adjuvant; no preservatives added.
Active Comparator: Pfizer PCV13; Primary Vaccination: A total of approximately 300 infants 6-8 weeks of age will be enrolled and assigned randomly to receive at 2, 4, and 12-15 months of age 1 dose of PCV13. Standard EPI vaccines will be administered concomitantly. Booster Vaccination: At 12-15 months of age (8 to 11 months after the 2nd dose of the primary series), infants will receive a booster dose of PCV13.	Biological: Pfizer PCV13; PCV13 is a suspension for intramuscular injection available in 0.5 mL single-dose prefilled syringes. Each 0.5 mL dose of PCV13 is formulated to contain approximately 2.2 μg of each of S. pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F polysaccharides, 4.4 μg of 6B polysaccharides, 34 μg 26 CRM197 carrier protein, 100 μg polysorbate 80, 295 μg succinate buffer and 125 μg aluminum as aluminum phosphate adjuvant.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Immunogenicity and non-inferiority as measured by serotype-specific IgG	Percentage of infants with serotype-specific IgG concentrations ≥0.35 μg/mL	1 month after the booster dose
Immunogenicity and non-inferiority as measured by serotype-specific IgG GMC	Serotype-specific IgG GMCs	1 month after the booster dose

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Solicited local and systemic adverse events after each dose	Frequency and severity of solicited local and systemic adverse events (AEs)	within 30 min and 7 days after each dose
Unsolicited adverse events after each dose	Frequency and severity of unsolicited AEs	within 30 days after each dose
Serious adverse events throughout the study	Frequency of serious AEs (SAEs)	from dose 1 until 6 months after booster dose
Immune response to primary series as measured by serotype-specific IgG	Percentage of infants with pneumococcal serotype-specific IgG concentrations ≥0.35 µg/mL	1 month after the 2nd dose
Immune response to primary series as measured by serotype-specific IgG GMC	Serotype-specific IgG GMCs	1 month after the 2nd dose
Functional antibody responses as measured by serotype-specific OPA titer	Percentage of infants with serotype-specific OPA titer ≥1:8	baseline, 1 month after the 2nd dose, before the booster dose, and 1 month after the booster dose
Functional antibody responses as measured by serotype-specific OPA geometric mean titers (GMTs)	Serotype-specific OPA geometric mean titers (GMTs)	baseline, 1 month after the 2nd dose, before the booster dose, and 1 month after the booster dose
Immune persistence as measured by serotype-specific IgG	Percentage of infants with pneumococcal serotype-specific IgG concentrations ≥0.35 µg/mL	12-15 months of age, before the booster dose
Immune persistence as measured by serotype-specific IgG GMC	Serotype-specific IgG GMCs	12-15 months of age, before the booster dose

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Exploratory_Non-interference	Percentage of infants with anti-diphtheria toxoid IgG concentrations ≥0.1 IU/mL	1 month after the 2nd dose
Exploratory_Non-interference	Percentage of infants with anti-tetanus toxoid IgG concentrations ≥0.1 IU/mL	1 month after the 2nd dose
Exploratory_Non-interference	Proportion of subjects with 4-fold increase in anti-pertussis IgG concentration	1 month after the 2nd dose with respect to baseline titers
Exploratory_Non-interference	Percentage of infants with anti Haemophilus influenzae type b (PRP) IgG concentration ≥0.15 µg/mL	1 month after the 2nd dose.
Exploratory_Non-interference	Percentage of infants with anti Hepatitis B surface antigen (hBsAg) IgG oncentrations ≥10 mIU/mL	1 month after the 2nd dose.
Exploratory_Non-interference	Percentage of infants with anti poliovirus types 1, 2 and 3 neutralizing antibody titers ≥1:8 measured	1 month after the 2nd dose.

Collaborators and Investigators

• Sponsor: Walvax Biotechnology Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): November 23, 2023
• Primary Completion (Estimated): December 1, 2024
• Study Completion (Estimated): September 1, 2025

Study Registration Dates

• First Submitted: June 28, 2023
• First Submitted That Met QC Criteria: June 28, 2023
• First Posted (Actual): July 7, 2023

Study Record Updates

• Last Update Posted (Estimated): December 14, 2023
• Last Update Submitted That Met QC Criteria: December 7, 2023
• Last Verified: December 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Infections; Bacterial Infections; Bacterial Infections and Mycoses; Streptococcal Infections; Gram-Positive Bacterial Infections; Pneumococcal Infections
• Other Study ID Numbers: PCV13-004

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No